Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
View Patent ↗The present invention relates to the discovery of novel biomarkers of in vivo apoptosis based on a large number of caspase-like cleavage sites. These biomarkers are useful for detection and quantification of apoptosis in a biological sample. The invention also provides synthetic peptides and proteins corresponding to neo-epitopes created by proteolytic processing of these cleavage sites. The synthetic peptides can be used as standards to enable identification and quantitation of these biomarkers using mass spectrometry. The synthetic proteins can be used to generate antibodies and other binding reagents specific for these biomarkers. Methods for detecting apoptosis as well as for diagnosing or for providing a prognosis for a disease or disease state characterized by apoptosis are also provided herein. Finally, the invention provides compositions and kits for performing the methods of the invention.
1. A method of detecting a proteolytic polypeptide in a subject, the method comprising the steps of:
(a) obtaining a sample from a subject;
(b) contacting a proteolytic polypeptide with an antibody in said sample, wherein said antibody specifically binds said proteolytic polypeptide relative to a corresponding proteolytic cleavage junction of said proteolytic polypeptide; and
(c) detecting binding between said proteolytic polypeptide and said antibody;
wherein said proteolytic polypeptide is a sequence selected from the group consisting of SEQ ID NO:1 through SEQ ID NO:401.
2. The method of claim 1 , wherein
step (b) comprises contacting a plurality of different proteolytic polypeptides with a plurality of different antibodies in said biological sample;
wherein said plurality of different proteolytic polypeptides are sequences selected from the group consisting of SEQ ID NO:1 through SEQ ID NO:401.
3. The method of claim 1 , wherein said proteolytic polypeptide is selected from the group consisting of:
SISSQLGPIHPPPR (SEQ ID NO:63),
SFGGDAQADEGQAR (SEQ ID NOs:172 and 173),
GVPSDSVEAAKNASNTEK (SEQ ID NOs:198 and 199),
GVPLDATEDSKKNEPIFK (SEQ ID NO:300),
GSETPQLFTVLPEKR (SEQ ID NO:283),
GLPEEQPQTTK (SEQ ID NO:107),
GLGVARPHYGSVLDNER (SEQ ID NO:122 and 123),
GGGPGQVVDDGLEHR (SEQ ID NOs:87 and 412),
AYEPQGGSGYDYSYAGGR (SEQ ID NO:100),
ASSASSFLDSDELER (SEQ ID NOs:239 and 240),
ALYVACQGQPK (SEQ ID NO:177),
GFDVASVQQQR (SEQ ID NO:153),
GLAVTPTPVPVVGSQMTR (SEQ ID NO:349),
GQSDENKDDYTIPDEYR (SEQ ID NO:164),
GLVETPTGYIESLPR (SEQ ID NOs:195 and 196),
GVPSDSVEAAK (SEQ ID NOs:197, 198 and 199),
AINTEFK (SEQ ID NOs:366, 367, 369 and 370),
SLADAINTEFKNTR (SEQ ID NO:370),
GFDQNVNVK (SEQ ID NO:223),
GLGLSYLSSHIANVER (SEQ ID NO:73),
AINTEFKNTR (SEQ ID NOs:367 and 370),
ALKGTNESLER (SEQ ID NO:368),
AVTPGPQPTLEQLEEGGPRPLER (SEQ ID NOs:120 and 121),
AVSGQLPDPTTNPSAGKDGPSLLVVEQVR (SEQ ID NO:150),
GVPVPGSPFPLEAVAPTKPSK (SEQ ID NOs:58, 59 and 60),
GVPSDSVEAAKNASNTEKLTDQVMQNPR (SEQ ID NO:199), and
ATVGGPAPTPLLPPSATASVK (SEQ ID NO:136).